Impact of nucleotide excision repair ERCC2 and base excision repair APEX1 genes polymorphism and its association with recurrence after adjuvant BCG immunotherapy in bladder cancer patients of North India

Gangawar, Ruchika; Ahirwar, Dinesh K.; Mandhani, Anil; Mittal, Rama Devi

doi:10.1007/s12032-009-9187-y

Cited by 27 publications

(21 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Before this study, an XPD polymorphism study was conducted on the same cancer in an Indian population (Gangawar et al, 2010) but it studied recurrence and progression of cancer with post-BCG immunotherapy. Moreover, the latter did not show any significant genotypic difference.…”

Section: Discussionmentioning

confidence: 99%

“…On the contrary, Stern et al (2002) found a slight decrease in risk for the Gln/Gln genotype compared with the subjects with the Lys/Lys or Lys/Gln genotypes. No associations for the XPD polymorphism were found in a Turkish population (Narter et al, 2009), in an Indian population (Gangawar et al, 2010), in three Italian populations (Shen et al, 2003;Matullo et al, 2005;Covolo et al, 2008), in American-Caucasians (Gu et al, 2005), and in a German population (Sanyal et al, 2004). Different population groups have different ethnicities.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Susceptibility ofXPDandRAD51Genetic Variants to Carcinoma of Urinary Bladder in North Indian Population

Sobti

Kaur²,

Sharma³

et al. 2012

DNA and Cell Biology

View full text Add to dashboard Cite

For the present study, two polymorphisms, xeroderma pigmentosum, complementation group D (XPD) Lys751Gln and RAD51 135G/C were studied with regard to bladder cancer. For XPD Lys751Gln polymorphism, an increased risk of bladder cancer was found to be associated with the Gln variant allele (odds ratio [OR]=1.86, 95% confidence interval [CI]=1.27-2.73), on taking AA (Lys/Lys) as the referent genotype. In males, the XPD 751C (Gln) allele was found to be associated with a significantly increased risk (OR=2.33, 95% CI=1.52-3.56). The inhabitants of rural areas showed a significantly increased risk with the XPD Gln allele (OR=2.59, 95% CI=1.46-4.62) when compared with those of urban areas. In smokers (OR=5.30, 95% CI=2.42-11.68), alcohol drinkers (OR=4.33, 95% CI=2.17-8.70), and nonvegetarians (OR=2.21, 95% CI=1.26-3.87), the XPD Gln allele showed a significantly increased risk toward bladder cancer. For RAD51 135G/C polymorphism, no significant difference was observed in the allelic and genotypic frequencies. Even after stratification, no significant association could be seen. After stratifying histopathologically, the RAD51 CC genotype was associted with decreased risk in subjects having superficial stage (OR=0.51, 95% CI=0.27-0.99) and with those having G2 grade (OR=0.24, 95% CI=0.09-0.62) of bladder cancer. XPD polymorphism may be a predisposing factor, but the same cannot be said for RAD51 gene polymorphism.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Susceptibility ofXPDandRAD51Genetic Variants to Carcinoma of Urinary Bladder in North Indian Population

Sobti

Kaur²,

Sharma³

et al. 2012

DNA and Cell Biology

View full text Add to dashboard Cite

show abstract

“…To summarize the best available evidence, we selected 12 studies that met the inclusion criteria for this review article of which five studies were published prior to 2011. The associations of smoking with disease recurrence and progression, the two most important disease outcomes in NMIBC, are summarized in Table 1 [11][12][13][14][15][16][17][18][19][20][21][22]. Although there are minor variations in disease outcome definitions among studies, the definitions were sufficiently similar to allow for evidence synthesis.…”

Section: Impact Of Smoking On Outcomesmentioning

confidence: 99%

“…The majority of studies (10 of 12) investigated the associations of smoking status with disease recurrence [11][12][13][14][15][16]17 19,20]. Attributable to variations in the study sample sizes, there were variations of the comparator groupings.…”

Section: Impact Of Smoking On Outcomesmentioning

confidence: 99%

“…Half of the studies investigated the association of smoking with disease progression with seven studies investigating the impact of smoking status [12,14,16 ] found a statistically significant association of smoking status (particularly, in current smokers compared with never smokers) with disease progression in NMIBC. In addition, a high cumulative exposure also seems to be associated with disease recurrence.…”

Section: Key Pointsmentioning

confidence: 99%

See 1 more Smart Citation

Smoking and smoking cessation effects on oncological outcomes in nonmuscle invasive bladder cancer

Simonis

Shariat

Rink

2014

Current Opinion in Urology

View full text Add to dashboard Cite

Although there are limited data, the growing body of evidence indicates that smoking increases the risk of disease recurrence and potentially disease progression in patients with NMIBC. Current and heavy long-term smokers seem to be at the greatest risk for both end points. Smoking cessation may limit these effects thereby improving prognosis. To improve our understanding of the associations of this important, modifiable risk factor with outcomes in patients with NMIBC, smoking should be incorporated into clinical trial design and analysis. It is the duty of each urologist to raise awareness regarding the greatest preventable cause of the development of bladder cancer, morbidity, and mortality.

show abstract

Polymorphisms in theXRCC1gene modify survival of bladder cancer patients treated with chemotherapy

et al. 2013

View full text Add to dashboard Cite

Survival of bladder cancer patients depends on several factors including disease stage and grade at diagnosis, age, health status of the patient and the applied treatment. Several studies investigated the role of DNA repair genetic variants in cancer susceptibility, but only few studies investigated their role in survival and response to chemotherapy for bladder cancer. We genotyped 28 single nucleotide polymorphisms (SNP) in DNA repair genes in 456 bladder cancer patients, reconstructed haplotypes and calculated a score for combinations of the SNPs. We estimated Hazard Ratios (adjHR) for time to death. Among patients treated with chemotherapy, variant alleles of five SNPs in the XRCC1 gene conferred better survival (rs915927 adjHR 0.55 (95%CI 0.32–0.94); rs76507 adjHR 0.48 (95%CI 0.27–0.84); rs2854501 adjHR 0.25 (95%CI 0.12–0.52); rs2854509 adjHR 0.21 (95%CI 0.09–0.46); rs3213255 adjHR 0.46 (95%CI 0.26–0.80). In this group of patients, an increasing number of variant alleles in a XRCC1 gene score were associated with a better survival (26% decrease of risk of death for each additional variant allele in XRCC1). By functional analyses we demonstrated that the previous XRCC1 SNPs confer lower DNA repair capacity. This may support the hypothesis that survival in these patients may be modulated by the different DNA repair capacity determined by genetic variants. Chemotherapy treated cancer patients bearing an increasing number of “risky” alleles in XRCC1 gene had a better survival, suggesting that a proficient DNA repair may result in resistance to therapy and shorter survival. This finding may have clinical implications for the choice of therapy.

show abstract

Impact of nucleotide excision repair ERCC2 and base excision repair APEX1 genes polymorphism and its association with recurrence after adjuvant BCG immunotherapy in bladder cancer patients of North India

Abstract: Our data suggested variant (AA) of ERCC2 312 AA genotype to be associated with high risk of tumor recurrence and reduced recurrence free survival in superficial bladder cancer patients.

Cited by 27 publications

References 27 publications

Susceptibility ofXPDandRAD51Genetic Variants to Carcinoma of Urinary Bladder in North Indian Population

Susceptibility ofXPDandRAD51Genetic Variants to Carcinoma of Urinary Bladder in North Indian Population

Smoking and smoking cessation effects on oncological outcomes in nonmuscle invasive bladder cancer

Polymorphisms in theXRCC1gene modify survival of bladder cancer patients treated with chemotherapy

Contact Info

Product

Resources

About